USA flag logo/image

An Official Website of the United States Government

PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60978
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
GM061460
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AGENTASE LLC
3636 Boulevard of the Allies, Suite B-17 Pittsburgh, PA 15213
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2002
Title: PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS
Agency: HHS
Contract: 2R44GM061460-02
Award Amount: $749,420.00
 

Abstract:

DESCRIPTION (provided by applicant): Agentase, LLC seeks follow-on Phase II Small Business Innovation Research funding to develop prototype formulations of chemically modified enzymes for the treatment and, more importantly, the prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent chemical weapons such as sarin and soman as well as many commercially available pesticides, including parathion, methyl parathion and chlorpyrifos. Many of these enzymes have been derived from bacterial sources and are unfortunately not conducive to use as an in-vivo medical treatment for a variety of reasons including acute antigenicity, poor enzyme stability, and brief in-vivo residence times. When one considers that annually 3 million cases of severe poisoning and 220,000 deaths worldwide are associated with OP pesticides, there are obviously unmet needs associated with their use. There is a clear need for technology capable of protecting individuals from overexposure to OP compounds. Successful Phase I research has demonstrated that the concept of protecting a person from an otherwise debilitating dose of OP toxins with chemically modified enzyme is viable. Modified OP hydrolyzing enzymes have potential utility as medical treatments for exposed individuals as well as preventative security for individuals at high risk of OP exposure. Such treatments have potential utility at hospitals, agricultural sites employing OP pesticides, civil defense treatment centers for chemical terrorism, and with the armed forces. Research will also be extended to other model systems of clinical relevance.

Principal Investigator:

Keith E. Lejeune
4122097298
KLEJEUNE@AGENTASE.COM

Business Contact:

Keith Lejeune
4122097298
KLEJEUNE@AGENTASE.COM
Small Business Information at Submission:

AGENTASE, LLC
AGENTASE, LLC 3636 BLVD OF THE ALLIES, STE B17 PITTSBURGH, PA 15213

EIN/Tax ID: 251821159
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No